| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (NCT04941365) | Institut du Cancer de Montpellier - Val d'Aurelle | 2022-07-07 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) (NCT05262413) | Qilu Pharmaceutical Co., Ltd. | 2022-02-28 |
| Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer (NCT05239533) | Memorial Sloan Kettering Cancer Center | 2022-02-16 |
| Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma (NCT05135832) | Herlev and Gentofte Hospital | 2021-12-13 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (NCT05122546) | City of Hope Medical Center | 2021-11-01 |
| A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT05119335) | NiKang Therapeutics, Inc. | 2021-10-26 |
| An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK (NCT05394493) | Pfizer | 2021-06-11 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040) | M.D. Anderson Cancer Center | 2021-04-14 |
| A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (NCT04522323) | MedImmune LLC | 2020-08-05 |
| Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (NCT04071223) | National Cancer Institute (NCI) | 2020-07-29 |
| Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (NCT04203901) | CoImmune | 2020-07-22 |
| Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma (NCT03229083) | University of Rochester | 2019-07-24 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574) | National Cancer Institute (NCI) | 2019-07-16 |
| CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (NCT03829111) | City of Hope Medical Center | 2019-05-14 |
| A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK (NCT03696407) | Ipsen | 2018-12-20 |
| Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. (NCT03647878) | Ipsen | 2018-09-24 |
| CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma (NCT03428217) | Calithera Biosciences, Inc | 2018-04-24 |
| A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma (NCT03339219) | Takeda | 2017-12-13 |
| Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment (NCT03200717) | Novartis Pharmaceuticals | 2017-11-14 |
| Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma (NCT03117309) | Michael B. Atkins, MD | 2017-04-24 |
| PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer (NCT02735252) | University of California, San Francisco | 2016-05-25 |
| Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (NCT02231749) | Bristol-Myers Squibb | 2014-10-16 |
| Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC (NCT02143492) | Argos Therapeutics | 2013-08-01 |
| Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma (NCT01727336) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2012-12-01 |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer (NCT01664182) | National Cancer Institute (NCI) | 2012-08-01 |
| Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma (NCT01513187) | Spanish Oncology Genito-Urinary Group | 2011-07-11 |
| Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors (NCT01381822) | Threshold Pharmaceuticals | 2011-06-01 |
| An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). (NCT01076010) | AVEO Pharmaceuticals, Inc. | 2010-03-01 |
| A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (NCT01030783) | AVEO Pharmaceuticals, Inc. | 2009-12-01 |
| AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib (NCT00853372) | Amgen | 2009-05-28 |
| Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib (NCT00486538) | AbbVie (prior sponsor, Abbott) | 2007-06-01 |
| AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib (NCT00467025) | Amgen | 2007-05-01 |
| Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma (NCT00494091) | Pfizer | 2007-02-01 |
| A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma (NCT00422019) | Amgen | 2007-01-01 |
| Dendritic Cell Based Therapy of Renal Cell Carcinoma (NCT00197860) | Inge Marie Svane | 2004-09-01 |
| Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment (NCT00425204) | Amgen | 2004-03-01 |
| Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 (NCT00425035) | Amgen | 2003-02-01 |